天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-013 天津红日药业股份有限公司 第八届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）第八届董事会第二十二次 会议于 2025 年 04 月 24 日在天津市武清开发区创业总部基地 B01 号楼公司会议 室以现场加通讯表决方式召开，会议通知于 2025 年 04 月 13 日以邮件、电话的 方式发出。会议应参加董事 11 人，实际参加会议的董事 11 人（其中以现场表决 方式出席会议的董事为 2 人）。本次会议以现场表决的董事分别为：非独立董事 蓝武军、孙武。本次会议由公司副董事长蓝武军先生主持（公司董事长吴文元先 生因外地出差，以通讯方式出席），公司全体监事及高级管理人员列席了会议。 本次会议召开符合《公司法》等相关法律法规和《公司章程》《公司董事会议事 规则》的有关规定。 会议由公司副董事长蓝武军先生主持，参会董事投票表决通过如下议案： 一、审议通过《关于制定<舆情管理制度>的议案》； 为提高 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-019 天津红日药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、审议程序 公司于 2025 年 4 月 24 日召开了第八届董事会第二十二次会议及第八届监 事会第十八次会议，审议通过了《关于 2024 年度利润分配预案的议案》，本议案 尚需提交公司 2024 年度股东大会审议。 二、利润分配预案的基本情况 天津红日药业股份有限公司 本次利润分配预案为2024年度利润分配。 经信永中和会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属 于母公司的净利润 21,467,322.65 元，加上年初未分配利润 4,828,784,918.38 元，减去本年度提取的法定盈余公积 16,481,484.23 元，减去分配以前年度实现 的未分配利润 90,124,645.11 元后，截至 2024 年 12 月 31 日，可供股东分配的 利润为 4,743,646,111.69 元。 根据证监会鼓励企业现金分红， ...

Financial Performance - The company's total operating revenue decreased by 5.34% compared to the same period last year, while operating profit fell by 92.76%[5]. - The net profit attributable to shareholders decreased by 95.76% year-on-year, primarily due to a decline in revenue and an increase in asset impairment provisions, which grew by 88.04%[5]. - Non-recurring gains and losses amounted to 29.07 million yuan, a decrease of 77.82% compared to the previous year, mainly due to reduced government subsidies[5]. - The company reported a revenue of RMB 1.2 billion for the fiscal year 2024, representing a year-over-year increase of 15%[25]. - The company achieved a revenue of 5.783 billion yuan, a year-on-year decrease of 5.34%[49]. - Net profit attributable to shareholders was CNY 21,467,322.65, down 95.76% from CNY 506,631,425.70 in the previous year[30]. - The net cash flow from operating activities decreased by 44.30% to CNY 852,244,831.66 from CNY 1,530,094,404.76 in 2023[30]. - Basic and diluted earnings per share fell by 94.12% to CNY 0.01 from CNY 0.17 in 2023[30]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, which was CNY -7,607,061.84 compared to CNY 375,550,639.28 in 2023, a drop of 102.03%[30]. - The company received government subsidies amounting to CNY 56,318,652.90, down from CNY 175,380,153.53 in 2023[36]. Market Strategy and Competition - The company is facing risks from intensified market competition in the traditional Chinese medicine sector, with new policies expanding market access to all qualified medical institutions[9]. - The company plans to enhance its product competitiveness by accelerating the development and filing of national and provincial standards, and improving cost, quality, and supply capabilities[10]. - The company is actively monitoring policy changes and focusing on market demand to drive innovation and new product development[8]. - The company aims to mitigate risks from price fluctuations in traditional Chinese medicine materials by establishing a price warning mechanism and optimizing procurement strategies[11]. - The company is focusing on expanding its market presence and enhancing product offerings in response to ongoing industry changes and consumer needs[39]. - The company plans to expand its market presence by entering three new provinces, aiming for a 10% market share in these regions within two years[25]. - The company is exploring strategic acquisitions to bolster its product portfolio, targeting companies with complementary technologies[25]. - A new partnership with a leading healthcare provider is anticipated to increase distribution channels by 40%[25]. - The company is exploring joint venture cooperation models and refined private domain operations to achieve scalable operations in its healthcare services[54]. Research and Development - Ongoing research and development efforts have led to the introduction of two new drug formulations, expected to enhance treatment efficacy by 30%[25]. - The company is actively involved in the development of new drugs and technologies, aiming to transition from a TCM manufacturer to a comprehensive health service provider[42]. - The company has invested RMB 50 million in upgrading its manufacturing facilities to enhance production capacity by 20%[25]. - Research and development expenses increased by 6.01% year-over-year to approximately ¥228.54 million, reflecting the company's commitment to innovation[76]. - The company has achieved production approval for multiple new drugs, enhancing its product pipeline in critical care and oncology[78]. - The company is focusing on the development of a smart supply chain for medical devices, utilizing information technology for digital management[49]. - The company has introduced a provincial postdoctoral workstation, marking a significant milestone in building a platform for high-end scientific research talent cultivation[53]. - The company is investing 100 million yuan in R&D for new technologies aimed at improving product efficiency and safety[147]. Corporate Governance and Management - The company has established a transparent performance evaluation and incentive mechanism for senior management, linking their compensation directly to performance outcomes[162]. - The company has a dedicated investor relations management system, enhancing communication with investors through various channels[164]. - The audit committee is responsible for reviewing financial information and overseeing internal controls, ensuring the effectiveness of risk management practices[164]. - The company has not bypassed shareholder meetings for significant matters, maintaining compliance with governance standards[159]. - The board of directors includes 11 members, with 4 independent directors, ensuring a balanced governance structure[161]. - The company is committed to improving corporate governance and internal control systems to protect the rights of all shareholders and promote sustainable development[158]. - The company respects and maintains the legitimate rights and interests of stakeholders, emphasizing social responsibility and balanced interests among all parties[165]. - The company operates independently from its controlling shareholder, with no interference in decision-making or operations during the reporting period[166]. - The company has a complete and independent business system, including procurement, production, sales, and R&D capabilities[167]. Future Outlook and Guidance - The company has provided a revenue guidance of RMB 1.5 billion for the next fiscal year, projecting a growth rate of 25%[25]. - The company plans to enhance its supply chain management, aiming for a 30% reduction in operational costs over the next two years[146]. - The company aims to enhance its digital operations by integrating advanced technologies like AI and big data to drive management transformation and innovative marketing models[149]. - The company plans to focus on high-quality development in its main business, particularly in the area of traditional Chinese medicine, with an emphasis on the academic value of its blood purification injection product[150]. - The company is expected to provide updated performance guidance in the upcoming quarters, reflecting the impact of recent leadership changes[176]. Subsidiary Performance - The subsidiary Hubei Yinuo reported a net profit of CNY 87.28 million, contributing significantly to the company's overall performance[145]. - The subsidiary Beijing Chaosi achieved a net profit of CNY 15.04 million, reflecting its operational success[145]. - The subsidiary Tianjin Dongfang reported a revenue of CNY 190.70 million, indicating strong market demand[145]. Shareholder Engagement - The participation rate in the 2024 first extraordinary general meeting was 38.15%[168]. - The participation rate in the 2024 second extraordinary general meeting was 33.06%[169]. - The participation rate in the 2024 third extraordinary general meeting was 33.12%[169]. - The participation rate in the 2023 annual general meeting was 33.36%, with a proposal regarding the revision of the remuneration and performance assessment management system not being approved[169]. Executive Compensation - The company reported a total remuneration of 11.9684 million yuan for 22 directors, supervisors, and senior management in 2024[191]. - The remuneration for directors and supervisors is determined by the shareholders' meeting, while senior management remuneration is decided by the board of directors[191]. - The company disclosed its remuneration practices and the actual payment situation in its financial report[192]. - Total pre-tax compensation for executives in 2024 is 1,196.84 million, showing a decrease compared to 2023 due to personnel changes and job position adjustments[193].

Financial Performance - The company's revenue for Q1 2025 was ¥1,392,772,566.61, a decrease of 4.82% compared to ¥1,463,378,271.09 in the same period last year[5] - Net profit attributable to shareholders was ¥60,329,743.62, reflecting a 3.80% increase from ¥58,120,874.65 year-on-year[5] - Total operating revenue for the current period is ¥1,392,772,566.61, a decrease of 4.8% from ¥1,463,378,271.09 in the previous period[21] - Net profit for the current period is ¥61,884,708.86, an increase of 13.7% compared to ¥54,398,108.68 in the previous period[22] - Total operating costs for the current period are ¥1,309,581,769.19, down 4.2% from ¥1,367,139,489.84 in the previous period[21] - Other comprehensive income after tax for the current period is ¥126,095.49, compared to a loss of ¥422,152.76 in the previous period[23] - The total comprehensive income for the current period is ¥62,010,804.35, an increase from ¥53,975,955.92 in the previous period[23] Cash Flow - The net cash flow from operating activities decreased by 24.47% to ¥103,952,295.10 from ¥137,623,131.48 in the previous year[5] - Cash inflow from operating activities is ¥1,468,822,592.88, a decrease from ¥1,503,435,403.84 in the previous period[25] - Cash outflows from operating activities totaled $1,364,870,297.78, remaining relatively stable compared to $1,365,812,272.36 last year[26] - The net cash flow from investing activities was -$42,862,870.22, an improvement from -$48,575,252.14 in the previous period[26] - Cash inflows from financing activities were $1,439,920.09, significantly lower than $10,694,044.17 in the prior year[26] - The net cash flow from financing activities was -$164,403,487.18, worsening from -$37,020,439.30 in the previous period[26] - The total cash and cash equivalents at the end of the period were $1,170,382,482.29, down from $1,599,338,522.53 at the end of the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,027,171,551.76, down 1.24% from ¥11,165,116,699.53 at the end of the previous year[5] - Total liabilities amount to ¥2,166,605,224.24, a decrease of 8.5% from ¥2,366,561,176.36 in the previous period[21] - Total current liabilities decreased to CNY 1,509,592,767.12 from CNY 1,621,148,001.05, a decline of about 6.9%[18] - Short-term borrowings decreased significantly from CNY 16,239,838.57 to CNY 11,454,471.14, a reduction of approximately 29.1%[18] - The total non-current assets decreased to CNY 4,942,907,856.61 from CNY 5,016,065,386.58, reflecting a decline of about 1.5%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 102,897, with the largest shareholder holding 22.24% of the shares[12] - The company reported a total of 263,602,455 shares subject to lock-up at the end of the period, an increase from 240,731,655 shares at the beginning[15] - The company has not disclosed any significant changes in the relationships or actions among the top shareholders[13] Other Financial Metrics - The weighted average return on equity increased to 0.70%, up from 0.67% in the same period last year[5] - Financial expenses decreased by 61.79% to ¥3.96 million, primarily due to reduced interest expenses[9] - The company reported a significant increase in other income, which rose by 40.91% to ¥1,028.93 million due to increased government subsidies[9] - Research and development expenses increased to ¥47,479,993.23, up from ¥44,359,218.24 in the previous period, reflecting a focus on innovation[22] - Cash outflows for employee compensation amounted to $268,565,434.64, an increase from $241,962,749.42 last year[26] - Tax payments totaled $148,305,973.39, slightly up from $141,228,651.82 in the previous period[26] - The impact of exchange rate changes on cash and cash equivalents was $573,452.99, contrasting with -$186,216.70 in the previous period[26] Strategic Developments - The company has not reported any new strategies or significant developments in product or technology during this period[16]

Financial Performance Expectations - The company expects a net profit attributable to shareholders of between 48 million and 62 million yuan for 2024, representing a decrease of 90.53% to 87.76% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses is projected to be between 20 million and 30 million yuan, down 94.67% to 92.01% from the previous year[3] - The impact of non-recurring gains and losses on the net profit attributable to shareholders is estimated to be between 28 million and 32 million yuan, primarily from government subsidies, a decrease of 75.59% to 78.64% year-on-year[5] Revenue and Profit Decline Factors - The overall revenue and profit of the company are declining due to factors such as falling terminal market prices, intensified competition, and rising production costs[5] Audit and Financial Data - The financial data in this earnings forecast has not been audited by registered accountants, but there are no disagreements with the annual audit firm regarding the earnings forecast[4]

证券代码：300026 证券简称：红日药业 公告编号：2025-009 天津红日药业股份有限公司 公司董事会、监事会的延期换届不会影响公司的正常生产经营，公司将根据 相关工作进展情况，积极推进董事会和监事会的换届工作，并及时履行信息披露 义务。 特此公告。 天津红日药业股份有限公司 天津红日药业股份有限公司 关于公司董事会、监事会延期换届的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）第八届董事会、监事会任 期将于 2025 年 4 月 21 日届满，公司正在积极筹备换届选举相关工作。鉴于公司 新一届董事会、监事会换届选举工作尚在筹备中为保证公司董事会、监事会工作 的连续性及稳定性，公司董事会、监事会的换届选举工作将适当延期，公司董事 会各专门委员会委员及高级管理人员的任期亦将相应顺延。 在董事会、监事会换届选举工作完成之前，公司第八届董事会及其专门委员 会全体成员、第八届监事会全体成员及高级管理人员将按照《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公 ...

本次权益变动后，姚小青持有公司股份300,415,428股，占公司总股本的10.0000%，触及5%的整数倍。 中国经济网北京4月18日讯红日药业（300026）(300026.SZ)昨日发布关于持股5%以上的股东减持股份变 动触及5%的整数倍及减持计划期限届满暨实施结果的公告。近日，公司收到姚小青出具的《告知 函》，获悉姚小青于2025年1月15日至2025年4月14日，通过集中竞价及大宗交易的方式合计减持公司股 份7,062,300股，占公司总股本的0.2351%。本次减持后，姚小青持有公司股份300,415,428股，占公司总 股本的10.0000%。同时，姚小青本次减持计划期限已届满。 截至公告披露日，本次减持计划实施期限已届满。减持计划期间，姚小青通过集中竞价及大宗交易的方 式合计减持公司股份7,062,300股，占公司总股本的0.2351%。依照减持均价，姚小青合计减持2429.8680 万元。 姚小青不是公司控股股东、实际控制人，本次股份减持计划的实施不会导致公司控制权发生变更，不会 对公司的治理结构及持续性经营产生重大影响。 天眼查APP显示，天津红日药业股份有限公司，成立于2000年，位于天 ...

天津红日药业股份有限公司简式权益变动报告书 天津红日药业股份有限公司 简式权益变动报告书 上市公司名称：天津红日药业股份有限公司 股票简称：红日药业 股票代码：300026 股票上市地点：深圳证券交易所 信息披露义务人：姚小青 住所/通讯地址：天津市河东区****** 权益变动性质：持股比例减少 签署日期：2025 年 4 月 17 日 1 天津红日药业股份有限公司简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》《中华人民共和国证券 法》（以下简称"《证券法》"）《上市公司收购管理办法》（以下简称"《收购办法》"） 《证券期货法律适用意见第 19 号——<上市公司收购管理办法>第十三条、第十 四条的适用意见》《公开发行证券的公司信息披露内容与格式准则第 15 号——权 益变动报告书》（以下简称"《准则 15 号》"）及其他相关的法律、法规和规范性 文件编写本报告书。 二、信息披露义务人为自然人，签署本报告书无需获得授权和批准。 三、依据《证券法》《收购办法》《准则 15 号》的规定，本报告书已全面披 露了信息披露义务人在天津红日药业股份有限公司（以下简称"红日药业"）中 ...

天津红日药业股份有限公司 近日，公司收到姚小青先生出具的《告知函》，获悉姚小青先生于2025年1月 15日至2025年4月14日，通过集中竞价及大宗交易的方式合计减持本公司股份 7,062,300股，占本公司总股本的0.2351%。本次减持后，姚小青先生持有本公司 股份300,415,428股，占本公司总股本的10.0000%。同时，姚小青先生本次减持 计划期限已届满，现将有关情况公告如下： 一、本次减持计划的具体实施结果暨权益变动涉及5%的整数倍情况 截至本公告披露日，本次减持计划实施期限已届满。减持计划期间，姚小青 先生通过集中竞价及大宗交易的方式合计减持本公司股份7,062,300股，占本公 司总股本的0.2351%。具体情况如下： 证券代码：300026 证券简称：红日药业 公告编号：2025-008 天津红日药业股份有限公司 关于持股 5%以上的股东减持股份变动触及 5%的整数倍 及减持计划期限届满暨实施结果的公告 持股5%以上的股东姚小青先生保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 天津红 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-007 天津红日药业股份有限公司 关于延期披露 2024 年年度报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）原计划于 2025 年 3 月 31 日披露《2024 年年度报告》。由于年度报告复核工作量较大，根据审计机构目前 的审计进度，审计工作完成时间晚于预期，年度审计报告无法在原计划的时间内 出具。本着审慎原则及对广大投资者负责的态度，同时为确保定期报告的质量和 信息披露的真实性、准确性和完整性，经向深圳证券交易所申请，公司将《2024 年年度报告》及相关公告的披露时间延期至 2025 年 4 月 28 日。 公司董事会对延期披露年度报告给投资者带来的不便深表歉意，敬请谅解。 《中国证券报》、《证券时报》、《上海证券报》、《证券日报》和巨潮资讯网 （www.cninfo.com.cn）为公司信息披露的指定报纸和网站，公司所有信息均以 在上述媒体披露的信息为准，敬请广大投资者谨慎决策，注意防范投资风险。 天津红日 ...